Purer, Less Costly Interferon for Hepatitis C and B Treatment

July 22nd, 2008 by

admin

The Taiwan-based biopharmaceutical consort PharmaEssentia Corp. is investigating P1101, its third-generation PEG-interferon-alpha take candidate. Because it is a longer-lasting, purer interferon that is inferior expensive to produce, P1101 could compound the communication options for Hepatitis C and B….

Tags: ATM, Treatment Option

Posted in Hepatology |

Related posts

Comments are closed.

Recent Posts

How to Find a Dentist
TV’s Influence On Going Under The Knife
Ivabradine Reduces Incidence Of Coronary Artery Disease Outcomes In Patients With High Heart Rate (Beautiful Study)
Omega-3 Polyunsaturated Fatty Acids Reduce Mortality And Hospital Admission In Patients With Heart Failure, Statins Show No Effect
Telmisartan Modestly Reduces Major Cardiovascular Events In Patients Unable To Tolerate Ace Inhibitors (Transcend Study)
Siemens’ New Ultrasound Platform Revolutionizes The Paradigm Of Echocardiography
Increased expression of matrilin-3 not only in osteoarthritic articular cartilage but also in cartilage-forming tumors, and down-regulation of sox9 via epidermal growth factor domain 1-dependent signaling
Researchers devise means to create blood by identifying earliest stem cells
Landmark study opens door to new cancer, aging treatments
Researchers discover atomic bomb effect results in adult-onset thyroid cancer

Categories

Archives:

Search: